PT-141 (Bremelanotide)

PT-141 PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide and melanocortin-receptor agonist. It is an analog of alpha-melanocyte-stimulating hormone and is used in laboratory research involving central melanocortin signaling, hypothalamic pathways, neurobehavioral responses, and melanocortin-receptor pharmacology. PT-141 interacts primarily with melanocortin receptors such as MC3R and MC4R. Although bremelanotide is the active ingredient in an FDA-approved prescription product, this research material is not an approved pharmaceutical formulation and must not be represented or used as one. Product Information Product: PT-141 Also known as: Bremelanotide Total content: 10 mg Compound type: Synthetic cyclic peptide Peptide length: 7 amino acids Research class: Melanocortin-receptor agonist Form: Lyophilized research material Purity: Refer to the lot-specific Certificate of Analysis Testing: Identity and purity documentation available by lot Storage: Store according to the conditions printed on the product label and Certificate of Analysis Research Applications PT-141 may be used in qualified laboratory investigations involving: MC3R- and MC4R-associated signaling Melanocortin-receptor pharmacology Hypothalamic neuronal activation Central nervous system signaling Dopaminergic and neurobehavioral pathways Sexual-behavior research models Autonomic nervous-system responses Receptor-binding and selectivity studies Alpha-MSH analog research Cyclic-peptide structure-activity relationships Comparative melanocortin-agonist studies Neuroendocrine signaling mechanisms Important Notice For research use only. Not for human or veterinary use. This product is supplied exclusively for controlled laboratory research by qualified professionals. It is not Vyleesi or any other FDA-approved pharmaceutical product. It is not intended for diagnosis, treatment, prevention, personal administration, pharmacy compounding, sexual-function enhancement, or any other clinical purpose. No dosing, reconstitution, administration, sexual-function, reproductive-health, or therapeutic guidance is provided or implied. Researchers are responsible for appropriate handling and compliance with all applicable requirements.